Edition:
United States

Amyris Inc (AMRS.O)

AMRS.O on Nasdaq

0.54USD
28 Apr 2017
Change (% chg)

$-0.01 (-1.62%)
Prev Close
$0.55
Open
$0.54
Day's High
$0.56
Day's Low
$0.53
Volume
1,672,588
Avg. Vol
2,571,785
52-wk High
$1.21
52-wk Low
$0.31

AMRS.O

Chart for AMRS.O

About

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $155.01
Shares Outstanding(Mil.): 286.47
Dividend: --
Yield (%): --

Financials

  AMRS.O Industry Sector
P/E (TTM): -- 16.05 113.14
EPS (TTM): -0.39 -- --
ROI: -388.94 5.62 10.63
ROE: -- 6.95 13.80

BRIEF-Amyris agrees to China manufacturing with Blue California

* Amyris agrees to exclusive China manufacturing with Blue California enabling continued record product revenue growth into Asian markets

Apr 18 2017

BRIEF-Amyris Inc files for non-timely 10-K

* Expects to file subject annual report on form 10-K for fiscal year ended Dec 31, 2016 on or before 15th calendar day following form 10-K’s due date Source text (http://bit.ly/2nx6ru2) Further company coverage:

Apr 03 2017

BRIEF-Amyris Q4 loss per share $0.14

* Amyris more than doubles revenues over 2015 and provides strong growth outlook

Mar 02 2017

BRIEF-Temasek Holdings reports 22.1 pct stake in Amyris as of Feb. 23

* Temasek holdings (private) ltd reports 22.1 percent stake in amyris inc as of feb 23 - sec filing

Feb 27 2017

BRIEF-Amyris says near-term debt maturities have been resolved

* Amyris Inc - near-term debt maturities have been resolved; completed strategic transition out of commodity products Source text for Eikon: Further company coverage:

Feb 03 2017

BRIEF-Temasek Holdings Pvt Ltd reports 23.2 percent stake in Amyris Inc

* Temasek Holdings (Private) Limited reports 23.2 percent stake in Amyris Inc as of January 6, 2017 versus 24.7 percent as of December 9,2016 Source text:(ID:http://bit.ly/2j7H97I) Further company coverage:

Jan 11 2017

BRIEF-Amyris achieves key milestone in major drug discovery collaboration

* Amyris achieves key milestone in major drug discovery collaboration Source text for Eikon: Further company coverage:

Nov 16 2016

BRIEF-Amyris reports Q3 loss per share $0.08

* Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 02 2016

More From Around the Web

Earnings vs. Estimates